-
-
-
-
-
-
-
Aptevo reports 87% clinical benefit rate in frontline AML trial
-
-
-
-
-
-
-
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
-
-
-
-
-
-
-
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
-
-
-
-
-
-
-
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
-
-
-
-
-
-
-
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
-
-
-
-
-
-
-
Aptevo Therapeutics (APVO) Halted on Volatility, Off Highs Following Offering
-
-
-
-
-
-
-
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
-
413,489 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

